Skip to main content

The Company held a presentation for analysts at 13:30CET/07:30ET on 28 October 2021.  To watch the recording of the call please follow the link below:

The call slides are available for download below.

"I look forward to the read-out of the registration enabling study for leniolisib, expected early in the new year, as a product with transformational potential for APDS patient’s lives and also transformational commercial potential for Pharming."

- Sijmen de Vries - CEO
Cookies: This website uses cookies Check the cookies page for more information Accept Decline